Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 12:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 1,706 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Human Immunodeficiency Virus Infection(HIV)/Acquired Immunodeficiency Syndrome (AIDS) Clear all

Conditions: HIV Infections
Interventions: Behavioral counseling, HIV-1 Antibody Test Kit; Other · Device
Lead sponsor: bioLytical Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 2,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 14
States / cities: Los Angeles, California • Palm Springs, California • San Diego, California + 8 more

Conditions: HIV Infections
Interventions: Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Day to 9 Months
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1996
U.S. locations: 41
States / cities: Birmingham, Alabama • Downey, California • Los Angeles, California + 26 more

Conditions: Healthy, HIV Infection
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections
Interventions: Stavudine; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 13 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1991
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Hiv
Interventions: Preventing AIDS Through Live Movement and Sound (PALMS); Behavioral
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 12 Years to 18 Years · Male only
Enrollment: 264 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: HIV, Pneumococcal Infections, Pneumococcal Vaccines
Interventions: PCV-13, PPSV-23; Biological
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2021
U.S. locations: 3
States / cities: Aurora, Colorado • Denver, Colorado

Conditions: Lymphoma, AIDS-related, Lymphoma, Large B-Cell, Diffuse
Interventions: Rituximab, Filgrastim, EPOCH; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Human Immunodeficiency Virus
Interventions: Aspirin, Atorvastatin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 2
States / cities: Bethesda, Maryland • Minneapolis, Minnesota

Conditions: Human Immunodeficiency Virus, Chronic Neuropathic Pain
Interventions: Low Dose Naltrexone; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: HIV (Human Immunodeficiency Virus)
Interventions: predictive emergency room alerts (pERA), Standard of care; Other
Lead sponsor: Hunter College of City University of New York; Other
Eligibility: 18 Years and older
Enrollment: 2,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Hepatitis C, HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 327 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2015
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland

Conditions: Human Immunodeficiency Virus
Interventions: IMB, Information-Only Control; Behavioral
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 17 Years to 24 Years · Male only
Enrollment: 118 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: HIV Infections
Interventions: Tenofovir gel, Tenofovir gel placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2010
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: HIV/AIDS
Interventions: iEngage; Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 15 Years to 21 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: HIV Infections, Hepatitis C
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 11
States / cities: Stanford, California • Miami, Florida • Honolulu, Hawaii + 7 more

Conditions: Anal Intraepithelial Neoplasia, High Grade Squamous Intraepithelial Neoplasia, HIV Positivity, Human Papillomavirus-16 Positive, Human Papillomavirus-18 Positive
Interventions: Electroporation, HPV DNA Plasmids Therapeutic Vaccine VGX-3100, Laboratory Biomarker Analysis; Device · Biological · Other
Lead sponsor: AIDS Malignancy Consortium; Network
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 7
States / cities: San Francisco, California • Atlanta, Georgia • Chicago, Illinois + 4 more

Conditions: Infection, Human Immunodeficiency Virus, HIV Infections
Interventions: YASMIN, GSK2248761, Placebo; Drug · Other
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Opiate Dependence, HIV Seropositivity, HIV Infections
Interventions: Clinic-based substance abuse treatment with buprenorphine, Case management and referred substance abuse treatment; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV Infections
Interventions: CAB LA + RPV LA, Oral ART; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 12 Years and older
Enrollment: 326 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 39
States / cities: Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 29 more

Conditions: Human Immunodeficiency Virus (HIV) Infection
Interventions: Doravirine, 2 NRTIs, DOR/3TC/TDF; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 4 Weeks to 11 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2034
U.S. locations: 2
States / cities: Aurora, Colorado • Atlanta, Georgia

Conditions: Infection, Human Immunodeficiency Virus
Interventions: BMS-663068; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Austin, Texas

Conditions: HIV Infections
Interventions: Indinavir sulfate, Lamivudine, Stavudine, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 1,750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1997
U.S. locations: 85
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 43 more

Conditions: HIV, Healthy Volunteers
Interventions: [6,6-2H2]-glucose; Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1998 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections
Interventions: HIV gp120/NefTat/AS02A Vaccine; Biological
Lead sponsor: Marcus Altfeld, M.D., Ph.D.; Individual
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Testing of INSTI™ HIV-1 Antibody Test Kit in Volunteer Subjects at Risk for HIV Infection

A Phase III Study to Evaluate the Safety, Tolerance, and Efficacy of Early Treatment With Zidovudine (AZT) in Asymptomatic Infants With HIV Infection

Immune Responses to HIV in Blood Cells in HIV-Infected and HIV-Uninfected Volunteers

A Study of Stavudine in HIV-Infected Patients Who Have Not Had Success With Other Anti-HIV Drugs

Evaluation of the Preventing AIDS Through Live Movement and Sound (PALMS) Intervention for Minority Adolescents

Mechanisms of Impaired HIV-associated B Cell and Pneumococcal Vaccine Responses

EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection

Elite Controller and ART-treated HIV+ Statin Versus ASA Treatment Intervention Study

Low Dose Naltrexone for Pain in Patients With HIV

Evaluating an Algorithm-Based Implementation Strategy to Improve HIV Care Outcomes

Leukapheresis for Research on HCV-Coinfected Patients

Mobile-health (mHealth) Intervention to Support HIV Self-testing and PrEP Uptake Among Young Men Who Have Sex With Men

Interventional Study of Mucosal and Antimicrobial Responses to Repeated Vaginal Applications of Tenofovir Gel in HIV Uninfected Women

Adolescents Living With HIV (ALWH): Social Networks, Adherence and Retention

Comparing Single Photon Emission Computed Tomography (SPECT) and Liver Biopsy to Evaluate the Liver in Patients With HIV and Hepatitis C Virus

VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions

A Study to Evaluate the Pharmacokinetics of an Oral Contraceptive When Co-administered With GSK2248761 in Healthy Adult Female Subjects.

Comparison of HIV Clinic-based Treatment With Buprenorphine Versus Referred Care in Heroin-dependent Participants

A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1

Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)

A Study to Assess the Effect of High Fat Meal and Increased Gastric pH on the Bioavailability of an Extended Release Formulation of BMS-663068 in Healthy Subjects

A Study of Indinavir Sulfate Plus Zidovudine (AZT) Plus Lamivudine in HIV-Infected Patients Who Have Taken AZT for Six or More Months

Use of Labeled Glucose to Study Lymphocyte Replication and Survival in HIV-Infected Patients

Study of the HIV gp120/NefTat/AS02A Vaccine to Treat Individuals With Chronic HIV-1 Infection on Highly Active Antiretroviral Therapy (HAART)